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The prevalence of obesity, which is a heritable trait that arises from the interactions of multiple genes and lifestyle factors,
continues to increase worldwide, causing serious health problems and imposing a substantial economic burden on societies.
For the past several years, various genetic epidemiological approaches have been utilized to identify genetic loci for obesity.
Recent evidence suggests that development of obesity involves hormones and neurotransmitters (such as leptin, cocaine- and
amphetamine-regulated transcript (CART), and ghrelin) that regulate appetite and energy expenditure. These hormones act on
speciﬁc centers in the brain that regulate the sensations of satiety. Mutations in these hormones or their receptors can lead to
obesity. Aberrant circadian rhythms and biochemical pathways in peripheral organs or tissues have also been implicated in the
pathology of obesity. More interestingly, increasing evidence indicates a potential relation between obesity and central nervous
system disorders (such as cognitive deﬁcits). This paper discusses recent advances in the ﬁeld of genetics of obesity with an
emphasis on several established loci that inﬂuence obesity. These recently identiﬁed loci may hold the promise to substantially
improve our insights into the pathophysiology of obesity and open up new therapeutic strategies to combat growing obesity
epidemic facing the human population today.
1.Introduction
Throughout history, sciencehas invested enormoustime and
eﬀort in the search to understand the physiological basis of
obesity. Crucial to this research are the inquiry of how does
our body control ingestion, digestion, absorption, and meta-
bolism and how nutrients are distributed among various
tissues, organs, and systems [1, 2]. Overweight and obesity,
deﬁned as body mass index (BMI, the weight in kilograms
divided by the square of the height in meters) >25 and >30,
respectively, are associated with premature death through
increased risk of many chronic diseases, including type 2
diabetes, cardiovascular disease, and cancer [3–5]. Obesity
is a major international public health threat and economic
burden.Overthe last 3decades, the prevalenceofoverweight
and obesity has increased rapidly. The latest World Health
Organization estimates that 1.6 billion adults (aged 15 years
and above) were overweight and 400 million were obese in
2005. These ﬁgures are predicted to rise to 2.3 billion over-
weight and over 700 million obese adults by 2015 [6].
Obesity results when body fat accumulates over time as
a result of chronic energy imbalance (calories consumed
exceed calories expended). In recent decades, obesity has
reached epidemic proportions in many populations whose
environments oﬀer an abundance of calorie-rich foods and
few opportunities for physical activities. Obesity is caused by
acomplexinteractionoftheenvironment,thegeneticpredis-
position, and human behavior, but the relative contribution
of these factors is still poorly understood. Environmental
factors are major contributors to the obesity epidemic. In
addition to environmental factors, there is genetic predis-
position to obesity. Although changes in genetic makeup of
populations may not be fully responsible for this rapid rise
in obesity, genetic predisposition does play a vital role in
the development of obesity. Genetic factors are estimated to
account for >40% of the population variation in BMI [7, 8].2 ISRN Endocrinology
Thus, genes inﬂuence how our bodies capture, store, and re-
lease energy from food.
How might genes contribute to obesity? Currently, there
are quite a few theories that (the thrifty gene hypothesis,
the fetal programming hypothesis, the predation release
hypothesis, the sedentary lifestyle hypothesis, the ethnic shift
hypothesis, the increased reproductive ﬁtness hypothesis, the
assortative mating hypothesis, and the complex hypothesis)
intend to explain the genetic basis of human obesity [9, 10].
However, an acceptable consensus in the ﬁeld is still lacking,
probably due to the fact that complex genetic interactions
inﬂuence the development of obesity. One of the intriguing
explanations for the rapid rise in obesity is the mismatch
between today’s environment and “energy thrifty genes”
that multiplied in the past under diﬀerent environmental
conditions when food sources were rather scarce. In other
words, according to the “thrifty genotype” hypothesis,
environments in which food is plentiful year around are
now challenging the same genes that helped our ancestors
surviveoccasionalfamines. Ithas beenarguedthatthethrifty
genotype is just part of a wider spectrum of ways in which
genes can favor fat accumulation in a given environment.
These ways include the desire to overeat; the tendency to be
sedentary; a diminished ability to utilize dietary fats as fuel;
an enlarged, easily stimulated capacity to store body fat
[11, 12]. The variation in how people respond to the
same environmental conditions is an additional indication
that genes play an important role in the development of
obesity [13]. This is also consistent with the notion that
obesity results from genetic variation interacting with shift-
ing environmental conditions. Recent advances in genetic
epidemiological approaches have identify several genetic loci
for obesity. This review will focus on several established
loci that inﬂuence obesity. Identifying the genetic factors
underlying the heritable risk of obesity will contribute to our
basic knowledge of the biology of energy balance, and might
even highlight molecules and signaling pathways that can be
targeted for therapeutic intervention.
2.ApproachestoIdentifyHumanObesityGenes
The genetic contributionto commonobesity has beenestab-
lishedthroughfamily,twin,andadoptionstudies.Twinstud-
ies have shown that genetic factors may contribute to >40%
of the variation in BMI while lower heritability has been
showninfamilies(>20%)andadoption(>20%),respectively
[7, 8, 14, 15]. Yet, despite a relatively high heritability, the
search for obesity susceptibility genes has been an arduous
task. Progress until recently has been slow and success
limited. Although recent success of genome-wide association
studies has drawn a lot of attention, gene identiﬁcation for
the last 15 years has been based on two broad genetic epide-
miological approaches, that is, candidate gene and genome-
wide linkage methods.
2.1.Candidate GeneApproach. The candidategeneapproach
is a hypothesis-driven approach that relies on current under-
standing on the biology and pathophysiology of the disease.
The candidacy of a gene for obesity is based on the fol-
lowing resources: animal models using gene knockout and
transgenic approaches; cellular model systems showing their
role in metabolic pathways involved in glucose metabolism;
linkage and positional cloning studies using extreme cases.
The concept of this approach is to identify an association
between a variant or mutation within or near the candidate
gene and a trait of interest (such as obesity). Candidate gene
approach needs to be on a large scale and well powered
in order to detect the expected small eﬀects of genetic
variants involved in common traits and disease [16, 17].
For example, neuropeptide cocaine- and amphetamine-
regulated transcript (CART) was reported as an endogenous
satiety factor [18]. Mutational screening of the CART gene
in obese children has identiﬁed a mutation (Leu34Phe)
associated with reduced resting energy expenditure and
obesity phenotype [19]. A recent study shows that a small
group of adolescents with the Leu34Phe mutation in the
CARTgeneexhibithigheranxietyanddepressionscoresthan
control subjects and develop severe early-onset obesity [20].
Results suggest a possible relationship between prevalence of
obesity andseverityof mentaldisorders, in which CARTmay
play a unique role [21].
Genotyping costs have come down substantially, and
publicly available datasets, such as dbSNP and the Interna-
tional HapMap, have provided deeper insight into genetic
variation in genes. This knowledge has led to more compre-
hensive studies that systematically examine the association
of all common variation in a gene of interest by means of
carefully selected tagSNPs and their haplotypes under the
assumption that a causal variant would be in high linkage
disequilibrium with one of the tagSNPs or at least captured
by the haplotypes [22]. Perhaps the most important ﬁnding
in hunting obesity gene occurred in 1994, when Zhang and
coworkers demonstrated for the ﬁrst time that an adipose-
derived hormone, leptin, plays a key role in regulating intake
and energy expenditure, including appetite and metabolism
[23, 24]. This discovery represented a huge step forward in
the study of obesity. Mutations in leptin and leptin receptor
genes have been associated with mild to extreme obesity
phenotype in human population [25–28].
Since1994,thenumberofproposedobesitysusceptibility
genes has grown steadily. The latest update of the Human
Obesity Gene Map reported 127 candidate genes for obesity-
related traits [29]. Results of large-scale studies suggest that
obesity is strongly associated with genetic variants in the
melanocortin-4 receptor (MC4R) gene, adrenergic β3 recep-
tor (ADRB3) gene, prohormone convertase 1 (PCSK1) gene,
brain-derived neurotrophic factor (BDNF) gene, and endo-
cannabinoid receptor 1 (CNR1) gene (Table 1). Relevance of
those putative genes confer to the development of obesity
has been recently summarized [9, 22]. Hypothalamic leptin-
melanocortin systemiscriticalforenergybalanceinhumans,
because disruption of this network causes the most severe
obesity phenotypes [30–32].
Notably,leptinadministration iseﬀectiveintreating obe-
sity. Long-term therapy with subcutaneous injections of re-
combinant leptin provided sustained beneﬁcial eﬀects on
lowering fat mass, hyperinsulinemia, and hyperlipidemia inISRN Endocrinology 3
Table 1: Overview of main obesity-susceptibility loci identiﬁed through candidate gene and genome-wide association studies.
Chromosomallocation Gene symbol Gene name
1p31.1 NEGR1 Neuronal growth regulator 1
1q41 LYPLA1 Lysophospholipase-like1
1q25.2 SEC16B SEC 16 homologue B
RASAL2 RAS protein activator like 2
2p25.3 TMEN18 Transmembrane protein 18
2q14.1 INSIG2 Insulin-induced gene 2
3q27 ETV5 Ets variant gene 5
4p13 GNPDA2 Glucosamine-6-phosphate deaminase 2
5q13.3 CART Cocaine-and amphetamine-regulated transcript
5q15-q21 PCSK1 Prohormoneconvertase 1/3
6p12 TFAP2B Transcription factor AP-2β
6p22.2-p21.3 PRL Prolactin
6q14-q15 CNR1 Endocannabinoid receptor 1
8p12-p11.2 ADRB3 Adrenergic β3 receptor
8p23.1 MSRA Methionine sulfoxide reductase A
10p12 PTER Phosphotriesterase related
11p11.2 MTCH2 Mitochondrial carrier homologue 2
11p13 BDNF Brain-derived neurotrophic factor
12q13 BCDIN3D BCDIN3-domain-containing
FAIM2 FAS apoptotic inhibitory molecule 2
14q31 NRXN3 Neurexin 3
16p11.2 SH2B1 SH2B adaptor protein 1
ATP2A1 ATPase, Ca2+ transporting, cardiac muscle, fast twitch 1
16q12.2 FTO Fat mass and obesity-associated gene
16q22-q23 MAF v Maf musculoaponeurotic ﬁbrosarcoma oncogene homologue
18q11-q12 NPC1 Niemann-Pick disease, type C1
18q22 MC4R Melanocortin 4 receptor
19q13.11 KCTD15 Potassiumchannel tetramerisation domain containing15
19q31 CHST8 Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase8
Xq23-24 SLC6A14 Solute carrier family 6 member 14
CUL4B Cullin 4B
human obese subjects [33]. These results suggest an impor-
tant role of leptin in the regulation of the human hypo-
thalamic-pituitary-thyroid axis. It is important to highlight
that this strategy is eﬀective for patients with leptin deﬁ-
ciency, butnot necessarily applicableas a treatment for com-
mon type of obesity.
2.2. Genome-Wide Linkage Studies. Genome-wide linkage
studies are hypothesis generating and, through surveying the
whole genome, aim to identify new, unanticipated genetic
variants associated with a disease or trait of interest. Ge-
nome-wide linkage studies rely on the relatedness of study
participants and test whether certain chromosomal regions
cosegregate with a disease or trait across generations [17]. A
whole-genome linkage survey requires 400–600 highly pol-
ymorphic markers, genotyped at 10cM intervals. Thus,
genome-wide linkage studies have a rather coarse resolution
and typically identify broad intervals that require follow-up
genotyping to pinpoint the genes that underlie the linkage
signal. Since the ﬁrst genome-wide linkage study was pub-
lished in 1997 [34], the number of chromosomal loci linked
to obesity-related traits has grown exponentially. The latest
Human Obesity Gene Map update reported 253 loci from
61 genome-wide linkage scans, of which 15 loci have been
replicated in at least three studies [29]. Yet, none of these
replicated loci could be narrowed down suﬃciently to pin-
point the genes or variants that underlie the linkage signal.
Despite substantial power, a meta-analysis of 37 genome-
wide linkage studies with data on >31,000 individuals from
10,000 families of European origin could not locate a single
obesity or BMI locus with convincing evidence [35]. This
meta-analysis indicates that genome-wide linkage analysis
might not be an eﬀective approach for identifying genetic
variants for common obesity.4 ISRN Endocrinology
2.3.Genome-Wide AssociationStudies. Genome-wide associ-
ation study is an approach used in genetics research to look
for associations between many (typically hundreds of thou-
sands) of speciﬁc genetic variations (most commonly,single-
nucleotide polymorphisms) and particular diseases or traits.
Similar to genome-wide linkage, the genome-wide associa-
tionapproach interrogates the entiregenome,unconstrained
by prior assumptions. Genome-wide association studies
(GWAS) screen the whole genome at higher resolution levels
than genome-wide linkage studies and are capable to narrow
down the associated locus more accurately. The genome-
wide association approach has eﬀectively replaced genome-
wide linkage approach for common disease [17, 22]. Three
waves of large-scale high-density genome-wide association
studies have led to a series of discoveries in the ﬁeld of
obesity genetics. Recent high-density multistage genome-
wide association analyses have so far discovered ∼30 loci
consistently associated with BMI and obesity-related traits
(Table 1). Recent excellent reviews have examined the impli-
cations of those loci to the development of human obesity
[9, 22, 36]. The strongest signal remains the association with
variants within FTO (the fat-mass and obesity-related gene)
[37–39] (described in more detail below). Other signals near
BDNF, SH2B1, and NEGR1 (all implicated in aspects of
neuronal function) reinforce the view ofobesity asa disorder
of hypothalamic function [36].
It should be emphasized early on that whilst heritable
factorsareknowntoexplainmuchoftheindividualvariation
in risk ofobesity,geneticfactors identiﬁed so far explain only
a small proportion of this risk. The signiﬁcance of this fact
encourages researchers to identify new DNA variants inﬂu-
encing disease predisposition, inorder to further understand
the disease pathology, and to develop eﬀective therapeutic
and preventive strategies. It should be also highlighted that
futurestrategiestoidentifythis“missing heritability”include
multiple methodological approaches, existing and novel. As
a powerful and successful approach, surely genome-wide
associationstudieswill identifymoresensitivegenesorsingle
nucleotide polymorphisms (SNPs) that inﬂuence BMI and
the risk of obesity in the future.
3.CandidateGenes forCommonObesity
As listed in Table 1, candidate gene approach and large-scale
high-density genome-wide association studies have identi-
ﬁed new loci for common obesity. The discovery of these
loci has initiated a series of experiments to explore the
pathophysiological mechanisms that underlie obesity devel-
opment, in particular to the fat mass and obesity-associated
(FTO) gene. In 2007, SNPs within the FTO became the
ﬁrst to be associated reproducibly with human body mass.
To date, of all identiﬁed loci, the genetic variation in FTO
has the largest eﬀect on obesity susceptibility [40]. FTO
encodes a Fe(II)- and 2-oxoglutarate-dependent oxygenase
putatively involved in DNA demethylation. Studies in
r o d e n t ss u g g e s t e dt h a tF T Om R N Ai sm o s ta b u n d a n ti nt h e
hypothalamic regions, which control energy homeostasis.
The FTO protein shows wide expression patterns in central
as well as peripheral regions [41]. Study also demonstrated
that increased adipose tissue FTO mRNA was associated
with increased BMI in healthy women [41]. FTO -null mice
have reduced fat mass, and mice with FTO overexpression
displayed increased energy intake and increased adiposity
[42, 43]. Despite recent progress, the mechanism by which
FTO inﬂuences human body mass remains elusive. Data
from rodents suggested that FTO might aﬀect neuropeptide
Y (NPY, a feeding stimulation or orexigenic factor) expres-
sion in the hypothalamus, which in turn impacts feeding
behavior [40]. Moreover, role of FTO in circadian rhythms
has been proposed [44]. Aberrant circadian rhythms have
been linked to metabolic disease and obesity [45].
Overall, multiple reports from genetics and epigenetic
studies have shown compelling evidence that FTO is the
strongest oneofhumanobesity causing genes, evenalthough
themechanisms bywhichFTOaﬀectobesityarestillnotfully
understood, the obesity risk alleles of FTO are gain of func-
tion. This also indicates that FTO is functionally involved in
energy homeostasis by the regulation of energy balance, via
food intake and/or energy expenditure.
Neuronal SH2B1 is essential for controlling energy and
glucose homeostasis. Deletion of the SH2B1 gene resulted
in metabolic disorders in SH2B1 knockout mice, includ-
ing hyperlipidemia, leptin resistance, hyperphagia, obesity,
hyperglycemia, insulin resistance, and glucose intolerance.
Neuron-speciﬁc restoration of SH2B1β not only corrected
the metabolic disorders in mice, but also improved JAK2-
mediated leptin signaling and leptin regulation of orexi-
genic neuropeptide expression in the hypothalamus [46].
Moreover, neuron-speciﬁc overexpression of SH2B1 dose-
dependently protected against high-fat diet-induced leptin
resistance and obesity. These observations suggest that neu-
ronal SH2B1 regulates energy balance, body weight, periph-
eral insulin sensitivity, and glucose homeostasis at least in
part by enhancing hypothalamic leptinsensitivity. Variations
close to or in the SH2B1 gene have been found to be associ-
ated with obesityintwolarge genome-wideassociation stud-
ies[47, 48].SH2B1deletionsare associated with severeearly-
onset obesity [31]. Genetic diﬀerences among people can
derive from lost or duplicated segments of chromosomes,
called copy number variants (CNV). Variation in gene copy
number can inﬂuence the activity of genes and accounts for
a signiﬁcant amount of genetic diﬀerence between people
[49]. A recent work of Farooqi et al. analyzed the genomes
of 300 obese children for missing or duplicated chromosome
segments.MutationsinLEPR,POMC,andMC4Rgeneswere
previously excluded by direct nucleotide sequencing. The
commonest CNV found in these patients was identiﬁed in
ﬁve unrelated children harboring overlapping deletions on
chromosome 16p11.2, which encompasses the gene SH2B1
[31]. The phenotype of the children with SH2B1-containing
deletionsischaracterizedbyextremehyperphagiaandfasting
insulin levels disproportionately elevated compared to age-
and obesity-matched controls. Deletions on chromosome
16p11.2 have been reported in an adult population with
severe obesity [50], further demonstrating the potential
importance in SH2B1 gene variation and the development
of human obesity.ISRN Endocrinology 5
Admixture mapping of 15,280 African Americans has
identiﬁed three loci, 5q13,3, Xq13.1, and Xq25, that may
harbor genetic variants associated with variations in BMI
[51]. The 95% conﬁdence interval (CI) for the chromosome
5peakcontainsCARTgene.Onlyafewstudiesreportlinkage
ofobesity with markers on the Xchromosome. Three studies
reported either suggestive or signiﬁcant linkage of obesity to
the q arm of chromosome X [52–54] and they all mapped to
the Xq23-q24 region, which overlaps with the 95% CI of the
highest admixture peak on chromosome X in this study. The
95%CIinthisstudycontainsoneparticulargenethatmaybe
a candidate for obesity susceptibility. The gene solute carrier
family 6 member 14 (SLC6A14) is involved in serotonin
synthesis and serotonergic receptor mechanisms that have
been implicated in appetite control and body weight regula-
tion [55]. Another potential candidate gene near the highest
admixture peak is the cullin 4B (CUL4B) gene. CUL4B was
recently identiﬁed as a causative gene for an X-linked mental
retardation syndrome, which was associated with several
clinical features, including central obesity [56].
4.CircadianRhythmsand
the PathogenesisofObesity
As mentioned previously, the discovery of leptin represents
a huge step in the study of obesity. Adipose tissue, until
then considered as inert and metabolically inactive, is now
regarded to be capable of producing proteins with autocrine,
paracrine, and endocrine activity. Further discovery have
shown that various adipokines, such as adiponectin, visfatin,
resistin are produced in adipose tissue and involved in the
pathophysiology of obesity [57]. Recent studies show that
many genes in adipose tissue show circadian rhythmicity
[58]. Microarrays carried out in animals and humans have
shown that approximately 7 to 21% of active genes expressed
in white and brown adipose tissue follow a daily rhythmic
pattern [59]. Indeed, adipose tissue has been seen to express
clock genes with a circadian rhythmicity, which is capable of
triggering thistissue and evenofmodulating othergenes, the
so-called Clock control genes [60]. Circadian oscillators play
an indispensable role in the coordination of physiological
processes with the cyclic changes in the physical environ-
ment. A signiﬁcant number of recent clinical and molecular
studies suggest that circadian biology may play an important
role in the regulation of adipose and other metabolic tissue
functions and circadian dysfunction may be involved in the
pathogenesis of obesity, type 2 diabetes, and the metabolic
syndrome [61]. In mammals, the “master clock” driving
circadian rhythm is located in the hypothalamic suprachi-
asmatic nucleus (SCN). The brain area contains neurons
whoseﬁringratesvaryoveranapproximately24-hourperiod
and, in turn, coordinates the oscillation of “slave clocks” in
other areas throughout the brain and periphery [62]. The
molecular mechanisms underlying these oscillations were
ﬁrstly described in Drosophila, but homologous genes have
beenidentiﬁedacrossdiversespecies.Thegenesencodingthe
core clock mechanisms include circadian locomotor output
cycles kaput (Clock), brain and muscle-Arnt-like 1 (Bmal1),
Period-1 (Per1), Period-2 (Per2), Period-3 (Per3), Crypto-
chrome-1 (Cry1), and Cryptochrome2 (Cry2) [62].
Mouse Clockgene was identiﬁed in 1997 [63, 64]. Recent
progress in our understanding of energy homeostasis may
provide further information about how the Clock genetic
variations confer obesity. A recent report from Turek et al.,
suggests that mutated Clock mice exhibited a near total loss
of selective nocturnal feeding, consuming close to 50% of
their daily food intake during the light phase. These mice
are hyperphagic and developobesity. The resultant obesity is
associated with increases in blood glucose, cholesterol, and
triglyceride levels, as observed in obese humans with the
metabolic syndrome [65]. The obese phenotype of Clock
mutant mice arises from loss of circadian rhythm is an
important ﬁnding. This observation is compatible with the
tight coupling between circadian clock and the patterns
of feeding and physical activity. Master clock-controlled
rhythms have been shown for blood glucose, glucose toler-
ance, and plasma leptin levels. Thus, it seems possible that
other metabolism-related functions are also subject to regu-
lation by the SCN or peripheral clocks [62]. Fluctuations in
body weight have been associated with changes in day length
in various species such as hamsters and sheep, suggesting a
central role for the circadian clock in regulating body weight
[62]. In humans, studies have demonstrated an increased
incidence of obesity among shift workers [66]. Circadian
clockplaysa majorrole in determining body weight byinﬂu-
encing the expression and secretion of hormones. Leptin 24-
hour levels were signiﬁcantly lower in obese compared with
nonobese adolescentgirls [67],suggestingthat bluntedcirca-
dianvariation mayplayaroleinleptinresistance andobesity.
Similarly to leptin, the rhythmic expression of resistin and
adiponectin was greatly blunted in obese mice [67, 68]. In
obese subjects, adiponectin levels were signiﬁcantly lower
than lean controls [69]. In rats, melatonin, a synchronizer
of the SCN clock, decreased weight gain in response to high-
fat diet and decreased plasma leptin levels. These eﬀectswere
independent of total food consumption [70].
5.Roleof NeuropeptidesinAppetite
RegulationandObesity
The central nervous system plays a key part in regulating
food intake through the brain-gut axis [30], with the hypo-
thalamus acting as the central regulator, receiving both
long- and short-term food intake and energy expenditure
feedback from the periphery. The hypothalamus integrates
these signals and acts through various downstream pathways
to maintain energy balance. The hypothalamus is a master
regulator of satiety, via production of pro-opiomelanocortin
(POMC) and CART. POMC undergoes tissue-speciﬁc post-
translational cleavage, with the product depending on the
endoproteases expressed in the tissue. In humans, leptin
stimulates POMC conversion into α-MSH in the arcuate
nucleus, which in turn binds to the MC4R, a key receptor
involvedin appetite controland energy homeostasis. Agouti-
related peptide(AgRP)is an antagonist ofMC4R. Mice over-
expressing AgRP or MC4R knockout mice are hyperphagic6 ISRN Endocrinology
and obese [71] and are insensitive to α-MSH. MC4R muta-
tions have been found in about 5.8% of adults with severe
childhood-onset obesity [72]. In another report it has been
shown that resequencingMC4Rresulted inthe identiﬁcation
of low-frequency coding variants that explain approximately
2 to 3% of cases of severe obesity [73]. Common variants
near MC4R are associated with fat mass, weight and risk
of obesity [74]. POMC deﬁciency could also lead to obesity
(due to lack of binding at MC4R), hypocortisolism (due to
the lack of binding of ACTH to the MC2R in the adrenal
gland), and alteration of pigment (due to lack of binding
at MC1R in the skin). This syndrome is deﬁned by severe
early onset obesity, adrenal insuﬃciency, and red hair [75].
Inrodentmodelsofcancer[76]and renalfailure[77],MC4R
antagonists attenuate cachexia by maintaining appetite, lean
body mass, and basal energy expenditure [78]. Thus, MC4R
antagonists may be useful to treat cachexia [79]w h i l eM C 4 R
agonists are being developed to treat obesity.
Anotherimportant satiety regulatorin thehypothalamus
is CART, which is coexpressed with POMC in arcuate neu-
rons in animals and humans [80]. CART is a hypothalamic
neuropeptide that transmits a physiological anorexigenic
signal and is involvedin appetite regulation. CARTknockout
mice have increased body weight compared with wild-type
mice [81]. Genomic regions containing the CART gene have
been linked to both BMI and serum leptin levels in a study
of French Caucasian families [82]. SNPs in the 5  upstream
region have been reported to be associated with obesity in
Japanese [83]a n dF r e n c h[ 84]. Similar to POMC neurons,
CART neurons are directly stimulated by leptin [18, 85].
CART neurons target areas throughout the hypothalamus
and are associated with reinforcement and reward, sensory
processing, and stress and endocrine regulation. CART ex-
pression also exhibits food-dependent diurnal rhythm in
blood and brain [86]. Animals deprived of food have de-
creased the expression of CARTmRNA.Intracerebroventric-
ular administration of CART in rats inhibits normal and
starvation-induced feeding, as well as blocking the NPY
feeding response [18, 85, 87].CARTmay be useful tocombat
obesity. However, clinical trial utilizing CART agonists or
antagonistsforweightregulationisstilllacking.CARTrecep-
tor has not been cloned. However, the ﬁrst interaction
partner forCARTwas recentlyidentiﬁedby yeast two-hybrid
system. Succinate dehydrogenase, a unique mitochondrial
protein of both the Krebs TCA cycle and complex II of the
electrontransport chain,isacrucialenzymeforintermediary
metabolismand energyproduction[88].Thus, thebiochem-
ical and physiological linkage between CART and energy
homeostasis has been ﬁrmly established.
Various peripheral neuropeptides regulate appetite and
inﬂuence the development of obesity. Of these, ghrelin, or
growthhormone-(GH-)releasingpeptide,istheonlyknown
circulating orexigen, or appetite stimulant. Ghrelin is gut
hormone.Ghrelin actsas amealinitiator asghrelin levelsrise
prior to meals, and falls quickly after ingestion of nutrients.
The ghrelin receptor, GH secretagogue receptor type 1a
(GHS-R1a), is a G-protein coupled receptor. Exogenous
ghrelin administration aﬀects glucose homeostasis, gut mo-
tility, pancreatic exocrine secretion, cardiovascular function,
immunity,andinﬂammation [89].Administrationofghrelin
to obese and lean human subjects leads to increased food
intake, in part by stimulating the production of NPY and
AgRP in the arcuate nucleus. Ghrelin may also alter energy
balance by stimulating adipogenesis, inhibiting apoptosis,
transitioning from fatty acid oxidation to glycolysis for
energy expenditure, and inhibiting sympathetic nervous sys-
tem activity. Future studies may examine ghrelin antagonists
as a therapeutic option for obesity [90, 91]. The biological
activities of ghrelin require octanoylation of the peptide
on Ser3, a posttranslational modiﬁcation that is catalyzed
by the enzyme ghrelin O-acyltransferase (GOAT). GO-Coa-
Tat, a peptide-based analog that antagonizes GOAT inhibits
GOAT in vitro, in cultured cells, and in mice. Intraperitoneal
administration of GO-Coa-Tat improves glucose tolerance
and reduces weight gain in wild-type mice but not in ghrelin
knockout mice [92], suggesting its beneﬁcial metabolic
eﬀects are due to speciﬁc GOAT inhibition. In addition to
ghrelin, many peripheral neuropeptides may also be asso-
ciated with satiety. The list of satiety peripheral hormones
is extensive. Important peripheral neuropeptides include
cholecystokinin (CCK), peptide YY (PYY3-36), pancreatic
polypeptide (PP), incretins, glucagon-like peptide-1 (GLP-
1), glucose-dependent insulinotropic polypeptide (GIP),
amylin, and bombesin. These peripheral hormones regulate
gastrointestinal functions such as motility, secretion, and
absorption and provide feedback to the central nervous
systemonavailabilityofnutrientsandmayplayanimportant
role in regulating energy intake.
6.Genesand Biochemical Pathwaysin
PeripheralOrgans/TissuesInﬂuence
EnergyHomeostasis
New strategies for gene identiﬁcation have emerged. One
source of novel intermediate phenotype with the utilization
of microarray technology has provided valuable informa-
tion on mRNA expression from thousands of genes in
tissues of interest. cDNA microarray analysis for the study
of obesity was ﬁrst reported by Soukas et al. in 2000, using
approximately 6,500 murine genes in pairs of adipose tissues
in ob/ob mice and wild-type lean mice [93]. This was fol-
lowed by many subsequentstudies. More than 30microarray
approaches have been exploited in assessing the changes in
gene expression in the adipose tissue, liver, hypothalamus,
skeletal muscles, small intestines, and kidneys of lean and
obese animals and human subjects. The data obtained
from these genomic investigations have provided a wealth of
informationaboutobesity-speciﬁc geneproﬁles.The overex-
pression ofgenesrelatedtoinﬂammation, immune response,
adhesion molecules, and lipid metabolism is a major char-
acteristic of white adipose tissue, while the overexpression
of the genes related to lipid metabolism, adipocyte diﬀer-
entiation, defense, and stress responses, is noticeable in the
nonalcoholic fatty liver of obese rodents [94]. The hepatic-
gene expression suggests that in obese rodents, the livers
are supplied with large amounts of fatty acids under condi-
tions associated with obesity either through increased fattyISRN Endocrinology 7
acid biosynthesis or through decreased fatty acid oxidation,
which may lead to increased mitochondrial respiratory
activity.
Brain-derived neurotrophic factor, BDNF, with its recep-
tor Trk B has been shown to regulate neuronal development
and plasticity and it is well established that BDNF plays a
role in the hypothalamic pathway that controls body weight
and energy homeostasis. Very interestingly, recent evidence
identiﬁes BDNF as a player not only in central metabolism,
but also in regulating energy metabolism in peripheral or-
gans, such as pancreatic islets and skeletal muscle [95, 96].
Similarly, peptide CART is also expressed in peripheral or-
gans, including adrenal glands and pancreatic islets [21].
This feature supports the idea that neurotrophic factors may
act via multiple pathways in controlling energy balance, dis-
ruption of the normal function and regulation in any levels
(center/global, local) may eventually aﬀect the development
of weight disorders.
7.OxidativeStressand Cognitive
DeﬁcitsinObesity
Oxidative stress is a key factor that is involved in many
chronic neurodegenerativediseases, includingthemain form
of dementia, Alzheimer’s disease [97, 98]. Oxidative stress
is also viewed as a primary mechanism linking obesity and
metabolic disorders [99]. Therefore, oxidative stress may be
a common mechanism for these complex diseases. Increased
evidence indicates that there is an association between
obesityandnervoussystemdisorders(cognitivedeﬁcits,neu-
rodevelopmental disorders, neurodegenerative diseases, and
psychiatricdisorders),includingdementiaandmajordepres-
sion.Theconditionsofchronicobesityandoverweightstatus
are risk factors for lower cognitive performance, cognitive
decline, cognitive deﬁcit, and dementia; on the other hand,
lower cognitive performance early in life itself may be a
risk factor for an increase in body weight over time [100].
Childhood overweight and obesity and their psychosocial
and cognitive consequences have been investigated in a
nationally representative sample of children. The association
between BMI and academic performance was not signiﬁcant
after adjusting for parental/familial characteristics. However,
the associations between BMI and cognitive functioning
remained signiﬁcant, and severe overweight correlates with
lower cognitive functioning [101].
Notably, recent investigations report a new highly pene-
trant form of obesity (or underweight) due to deletions (or
reciprocal duplications) on chromosome 16p11.2, that is
oftenassociatedwithhyperphagiaandintellectualdisabilities
[50, 102], indicating a pathological connection between
weight disorders and nervous system diseases in genomic
level. The reciprocal impact of these 16p11.2 copy-number
variants also indicates that severe obesity and being under-
weight could have mirror etiologies, possibly through con-
trasting eﬀects on energy balance. The precise mechanisms
underlining the phenotypes/disorders are currently unclear,
but they are worth further exploring. Interestingly some
g e n e sh a v eb e e ns h o w nt ob ei n v o l v e di nb o t ho b e s i t ya n d
CNSdisorders, suchas neurotrophinBDNFand neurotrans-
mitter CART [21, 103, 104].
8.The CriticalRoleofLifestyleonObesity
Genetic alterationsincludingmutations, deletions,and SNPs
only explain a small part of obesity, but the total number of
obesity has been signiﬁcantly increasing in recent decades.
Therefore, it may be more importantly that lifestyle changes
in the last decades have greatly contributed to the current
obesity trends. Itis widely known that diet and dietary habits
as well as less or lack of exercises do play a role in the
development of obesity.
D i e t a r yf a c t o r sm a ym o d i f yb o d yw e i g h ta sw e l la so b e -
sity. There is even controversy concerning the role of sugar
in the epidemics of obesity and metabolic syndrome, there is
less controversy concerning the eﬀects of fructose on obesity
and metabolic syndrome. Increasing evidence that sugar
consumption promotes development of an unfavorable lipid
proﬁle is strong and suggests that the upper added sugar
consumption limit of 25% energy or less, suggested in the
ReportoftheDietary GuidelinesAdvisory Committeeonthe
Dietary Guidelines for Americans 2010, may merit reevalua-
tion [105].
On the other hand, evidence from a variety of animal
models including rodents and nonhuman primates indicates
that exposure to maternal high-fat diet (HFD) consumption
programs oﬀspring for increased risk of adult obesity [106].
Hyperphagia and increased preference for fatty and sugary
foods are implicated as mechanisms for the increased obesity
risk. Using a nonhuman primate model of diet-induced
obesity,maternalHFDconsumptioncausedperturbationsin
thecentral serotonergic system offetal oﬀspring.Inaddition,
female infants from HFD-fed mothers exhibited increased
anxiety in response to threatening novel objects. These
ﬁndings demonstrate that exposure to maternal HFD con-
sumptionduring gestation, independentofobesity,increases
the risk of developing behavioral disorders such as anxiety
[107]. As maternal HFD consumption and obesity are
commonandrapidly increasing, itwasspeculatedthatfuture
generations will be at increased risk for both metabolic and
mental health disorders. Reduced physical activity and/or
increasing sedentary behavior, such as television viewing, is
implicated in the etiology of obesity. Deﬁnitive evidence of a
role for reduced physical activity and energy expenditure in
the causation of obesity is lacking. However, there is stronger
evidence that targeting activity and/or inactivity might be
eﬀective in pediatric obesity treatment [108].
As mentioned early, BDNF has been shown to regulate
neuronal development and plasticity and plays a role in
learning and memory. Low levels of BDNF are found in
patients with neurodegenerative diseases, including Alz-
heimer’s disease and major depression. In addition, BDNF
levels are low in obesity and independently so in patients
with type 2 diabetes. Interestingly it has been shown that
exercise increases BDNF levels not only in the brain and in
plasma, but in skeletal muscle as well [109]. BDNF mRNA
and protein expression was increased in muscle cells that8 ISRN Endocrinology
were electrically stimulated, and BDNF increased phospho-
rylation ofAMP-activated protein kinase (AMPK) and acetyl
coenzyme A carboxylase-beta (ACCbeta)and enhanced fatty
oxidation both in vitro and ex vivo. Thus, BDNF appears
to play a role both in neurobiology and in central as well
as peripheral metabolism. The ﬁnding of low BDNF levels
both in neurodegenerative diseases and in type 2 diabetes
may explain the clusteringof these diseases. Therefore BDNF
is likely to mediate some of the beneﬁcial eﬀects of exercise
with regard to protection against dementia, obesity, and type
2d i a b e t e s[ 109].
9.Summaryand FutureDirections
Obesity is inﬂuenced by a complex interaction between the
environment, genetic predisposition, and human behavior.
It is associated with an increased risk of numerous chronic
diseases. It is also associated with an increased risk of death
inpopulationsofEuropeanancestry andblackwomen[110].
As a result, obesity epidemic exerts a heavy toll on the
economy with its massive health care costs. There is growing
evidence that genetic predisposition confers obesity. Never-
theless,despitetheenormoussuccessofgenetic studies,there
are still important gaps in this knowledge. The established
loci in combination can only explain <2% of interindividual
v a r i a t i o ni nB M I[ 111]. Given that the heritability of BMI is
estimated at 40–70%, it is reasonable to assume that many
more susceptibility loci remain to be uncovered. To this
task, powerful genome-wide association studies and other
genome-level approaches are expected to be utilized widely,
including large-scale genome-wide resequencing and global
level of corporation.
Ofinterest isthatmany ofthecurrentlyidentiﬁedobesity
susceptibility loci locate near genes that are highly expressed
in the brain especially hypothalamus, favoring a role for the
nervous system in body weight control. Latest reports have
shown the association between obesity and CNS disorders,
such as cognitive defects. Central and peripheral neuropep-
tides regulate appetite and energy expenditure and may play
an important role in the development of obesity. Recent
studies also suggest that obesity may be associated with a
fault in the circadian system. Adipose tissue is capable to
produce protein with autocrine, paracrine, and endocrine
activity.Adipokinessuchasadiponectin,visfatin,andresistin
are involved in the physiology of obesity and those genes
show circadian rhythmicity. Furthermore, obesity-speciﬁc
gene expression proﬁling in various peripheral tissues may
help in understanding the pathogenicmechanisms ofobesity
and its associated metabolic diseases.
Recent advances in identifying genetic risk factors for
obesity have contribution to understanding disease pathol-
ogy, which may facilitate the formation of new therapeutic
strategies, including personalized medicine.
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